AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29891011 — intervention group
Group type: EXPERIMENTAL
Intervention: New Start intervention
Number of subjects: 0
Study 29891011 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 26153783 — intervention group
Group type: EXPERIMENTAL
Intervention: Distributed practice (practice blocks spaced in time)
Number of subjects: 40
Study 26153783 — intervention group
Group type: COMPARATOR
Intervention: Massed practice (all practices performed in 1 day)
Number of subjects: 40
Study 26153783 — intervention group
Group type: COMPARATOR
Intervention: Simulator‐integrated tutor function
Number of subjects: 40
Study 23764867 — intervention group
Group type: COMPARATOR
Intervention: Heated humidifier (HH)
Number of subjects: 29
Study 23764867 — intervention group
Group type: COMPARATOR
Intervention: Heat and moisture exchanger (HME)
Number of subjects: 29
Study 23205917 — intervention group
Group type: EXPERIMENTAL
Intervention: Subantimicrobial dose doxycycline (SDD)
Number of subjects: 128
Study 23205917 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study 19577808 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifrontal (BF) ultra-brief ECT at 1.5 times seizure threshold (ST)
Number of subjects: 64
Study 19577808 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral (UL) ultra-brief ECT at 6 times seizure threshold (ST)
Number of subjects: 64
Study 18655558 — intervention group
Group type: EXPERIMENTAL
Intervention: Fulu Baoxinping (FLBXP) oral liquid 10 mL thrice a day for 28 days
Number of subjects: 240
Study 18655558 — intervention group
Group type: COMPARATOR
Intervention: Wenxin Granule 9 g thrice a day for 28 days
Number of subjects: 240
Study 15936933 — intervention group
Group type: EXPERIMENTAL
Intervention: BUD/F (2x100/6 microg) administered in the evening (2000 h)
Number of subjects: 20
Study 15936933 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 12651656 — intervention group
Group type: EXPERIMENTAL
Intervention: Ephedrine 70 microg/kg
Number of subjects: 120
Study 12651656 — intervention group
Group type: EXPERIMENTAL
Intervention: Ephedrine 110 microg/kg
Number of subjects: 120
Study 12651656 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 120
Study 10655024 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg once daily
Number of subjects: 97
Study 10655024 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg twice daily
Number of subjects: 97
Study 9007884 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural morphine (10 mg)
Number of subjects: 0
Study 9007884 — intervention group
Group type: COMPARATOR
Intervention: Control group (no epidural morphine)
Number of subjects: 0
Study 1505054 — intervention group
Group type: EXPERIMENTAL
Intervention: Levoprotiline
Number of subjects: 58
Study 1505054 — intervention group
Group type: COMPARATOR
Intervention: Maprotiline
Number of subjects: 58
Study 29618079 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand massage (two 20-minute sessions)
Number of subjects: 60
Study 29618079 — intervention group
Group type: COMPARATOR
Intervention: Hand holding (two 20-minute sessions)
Number of subjects: 60
Study 29618079 — intervention group
Group type: COMPARATOR
Intervention: Standard care (two 20-minute rest periods)
Number of subjects: 60
Study 26891115 — intervention group
Group type: EXPERIMENTAL
Intervention: DACC impregnated dressing
Number of subjects: 543
Study 26891115 — intervention group
Group type: COMPARATOR
Intervention: Standard surgical dressing (SSD)
Number of subjects: 543
Study 24957557 — intervention group
Group type: EXPERIMENTAL
Intervention: IMN-RT (Internal Mammary Node Radiotherapy)
Number of subjects: 68
Study 24957557 — intervention group
Group type: COMPARATOR
Intervention: IMN-RT simulation (for left-sided patients)
Number of subjects: 68
Study 24957557 — intervention group
Group type: EXPERIMENTAL
Intervention: IMN-RT
Number of subjects: 68
Study 24957557 — intervention group
Group type: EXPERIMENTAL
Intervention: IMN-RT (for right-sided patients)
Number of subjects: 68
Study 22730932 — intervention group
Group type: EXPERIMENTAL
Intervention: Tooty Fruity Vegie intervention
Number of subjects: 18
Study 20837588 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (moderately early treatment)
Number of subjects: 721
Study 20837588 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (delayed treatment)
Number of subjects: 721
Study 18303192 — intervention group
Group type: EXPERIMENTAL
Intervention: Galantamine treatment
Number of subjects: 138
Study 18303192 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 138
Study 16491309 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical Impedance Scanning (EIS) with Clinical Breast Examinations (CBE) on 189 women prior to scheduled breast biopsy.
Number of subjects: 1550
Study 16491309 — intervention group
Group type: COMPARATOR
Intervention: Electrical Impedance Scanning (EIS) on 1361 asymptomatic women visiting clinics for routine annual well-woman examination.
Number of subjects: 1550
Study 16491309 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive EIS examination in women.
Number of subjects: 1550
Study 14578147 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized psychoeducational intervention
Number of subjects: 558
Study 14578147 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 558
Study 10872642 — intervention group
Group type: EXPERIMENTAL
Intervention: Netilmicin
Number of subjects: 281
Study 9344701 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-GAD positive NIDDM-SF patients
Number of subjects: 420
Study 9344701 — intervention group
Group type: EXPERIMENTAL
Intervention: NIDDM-SF patients
Number of subjects: 420
Study 9344701 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of serological marker (anti-GAD) and genetic marker (HLA-DRB1)
Number of subjects: 420
Study 8410865 — intervention group
Group type: EXPERIMENTAL
Intervention: Active SAS unit
Number of subjects: 23
Study 8410865 — intervention group
Group type: COMPARATOR
Intervention: Inactive placebo unit
Number of subjects: 23
Study 3513347 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic oophorectomy
Number of subjects: 280
Study 3513347 — intervention group
Group type: COMPARATOR
Intervention: Control group (no oophorectomy)
Number of subjects: 280
Study 29794545 — intervention group
Group type: EXPERIMENTAL
Intervention: Telerehabilitation (video clips of rehabilitation exercises focusing on lower limbs, 6 weeks, 3 sessions/week)
Number of subjects: 40
Study 29794545 — intervention group
Group type: COMPARATOR
Intervention: Control (exercise booklet, 6 weeks, 3 sessions/week)
Number of subjects: 40
Study 26773777 — intervention group
Group type: EXPERIMENTAL
Intervention: Green tea extract (GTE) capsules at a dose of 1 g total catechin, primarily gallated type
Number of subjects: 24
Study 26773777 — intervention group
Group type: EXPERIMENTAL
Intervention: Green tea extract (GTE) capsules
Number of subjects: 24
Study 26773777 — intervention group
Group type: EXPERIMENTAL
Intervention: Green tea extract (GTE) intake
Number of subjects: 24
Study 25262522 — intervention group
Group type: EXPERIMENTAL
Intervention: Danhong injection 20 ml
Number of subjects: 72
Study 25262522 — intervention group
Group type: COMPARATOR
Intervention: Blood producing needle 400 mg (Control)
Number of subjects: 72
Study 25262522 — intervention group
Group type: COMPARATOR
Intervention: Comparison between experimental group and control group after treatment
Number of subjects: 72
Study 22475545 — intervention group
Group type: EXPERIMENTAL
Intervention: anti-von Willebrand factor (vWF) Nanobody
Number of subjects: 110
Study 22475545 — intervention group
Group type: COMPARATOR
Intervention: plasma exchange (as adjunctive therapy)
Number of subjects: 110
Study 20078491 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05 mg nicotine yield cigarettes
Number of subjects: 0
Study 20078491 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg nicotine yield cigarettes
Number of subjects: 0
Study 20078491 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg nicotine lozenge
Number of subjects: 0
Study 18329602 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight Maintenance Intervention (MI) for 6 weeks after a 16-week behavioral weight loss program (BWLP)
Number of subjects: 51
Study 18329602 — intervention group
Group type: COMPARATOR
Intervention: No Contact (NC) after a 16-week behavioral weight loss program (BWLP)
Number of subjects: 51
Study 15776771 — intervention group
Group type: EXPERIMENTAL
Intervention: Tazarotene 0.1% cream, once daily for 12 weeks
Number of subjects: 173
Study 15776771 — intervention group
Group type: COMPARATOR
Intervention: Adapalene 0.1% cream, once daily for 12 weeks
Number of subjects: 173
Study 12463291 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate (specialists)
Number of subjects: 2
Study 12463291 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate (generalists)
Number of subjects: 2
Study 12463291 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (specialists)
Number of subjects: 2
Study 12463291 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (generalists)
Number of subjects: 2
Study 12463291 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha1-blockers (specialists)
Number of subjects: 2
Study 12463291 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha1-blockers (generalists)
Number of subjects: 2
Study 12463291 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride (specialists)
Number of subjects: 2
Study 12463291 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride (generalists)
Number of subjects: 2
Study 10048071 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-operative neuromonitoring based on electrical stimulation of peripheral mixed nerve (tibial and median) and intra-operative subpial recording of conducted and interneuronic SEP from the dorsal surface of the spinal cord.
Number of subjects: 30
Study 10048071 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-operative neuromonitoring
Number of subjects: 30
Study 8835620 — intervention group
Group type: EXPERIMENTAL
Intervention: Single oral dose of mefloquine 1250 mg
Number of subjects: 18
Study 8835620 — intervention group
Group type: EXPERIMENTAL
Intervention: Divided doses of mefloquine (750 mg and 500 mg at 6-h intervals)
Number of subjects: 18
Study 1823905 — intervention group
Group type: EXPERIMENTAL
Intervention: IMREG-1
Number of subjects: 0
Study 1823905 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6119182 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone (100 mg/day)
Number of subjects: 35
Study 6119182 — intervention group
Group type: COMPARATOR
Intervention: Chlorthalidone + beta-blocker
Number of subjects: 35
Study 6119182 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone (100 mg/day) in subgroup IA (11 men)
Number of subjects: 35
Study 6119182 — intervention group
Group type: COMPARATOR
Intervention: Withdrawal of beta-blocker in subgroup IB (5 men, 2 post-menopausal women)
Number of subjects: 35
Study 6119182 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopamide (5 mg/day) in group II (18 men)
Number of subjects: 35
Study 6119182 — intervention group
Group type: COMPARATOR
Intervention: Clopamide + pindolol (10 mg/day)
Number of subjects: 35
Study 31801373 — intervention group
Group type: EXPERIMENTAL
Intervention: High serum bilirubin levels
Number of subjects: 25406
Study 30616288 — intervention group
Group type: EXPERIMENTAL
Intervention: Blue filter lens (BB)
Number of subjects: 29
Study 30616288 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultraviolet blocking lens (UV)
Number of subjects: 29
Study 30616288 — intervention group
Group type: COMPARATOR
Intervention: Age-adjusted controls (AACs)
Number of subjects: 29
Study 28397697 — intervention group
Group type: EXPERIMENTAL
Intervention: Leucovorin and fluorouracil plus nab-paclitaxel
Number of subjects: 114
Study 28397697 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine plus nab-paclitaxel
Number of subjects: 114
Study 24773119 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive educational intervention (n=133)
Number of subjects: 284
Study 24773119 — intervention group
Group type: COMPARATOR
Intervention: No intervention (n=151)
Number of subjects: 284
Study 23584593 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 PUFA 1 g/day
Number of subjects: 48
Study 23584593 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 23584593 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 48
Study 22010913 — intervention group
Group type: EXPERIMENTAL
Intervention: Earlier ART (2 weeks after starting tuberculosis treatment)
Number of subjects: 661
Study 22010913 — intervention group
Group type: COMPARATOR
Intervention: Later ART (8 weeks after starting tuberculosis treatment)
Number of subjects: 661
Study 22010913 — intervention group
Group type: EXPERIMENTAL
Intervention: Earlier ART
Number of subjects: 661
Study 22010913 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 661
Study 19251586 — intervention group
Group type: EXPERIMENTAL
Intervention: Mastery goal condition
Number of subjects: 324
Study 19251586 — intervention group
Group type: EXPERIMENTAL
Intervention: Normative performance goal condition
Number of subjects: 324
Study 19251586 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-normative performance goal condition
Number of subjects: 324
Study 19251586 — intervention group
Group type: EXPERIMENTAL
Intervention: Performance-normative condition
Number of subjects: 324
Study 19251586 — intervention group
Group type: COMPARATOR
Intervention: Performance non-normative condition
Number of subjects: 324
Study 16923621 — intervention group
Group type: EXPERIMENTAL
Intervention: Spirometry and brief smoking cessation advice, annually for three years
Number of subjects: 0
Study 16923621 — intervention group
Group type: EXPERIMENTAL
Intervention: Smokers with COPD
Number of subjects: 0
Study 16923621 — intervention group
Group type: COMPARATOR
Intervention: Smokers with normal lung function
Number of subjects: 0
Study 14674053 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefazodone (up to 600 mg daily)
Number of subjects: 28
Study 10965288 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy by allocation
Number of subjects: 66
Study 10965288 — intervention group
Group type: COMPARATOR
Intervention: Cognitive therapy by preference
Number of subjects: 66
Study 8981691 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed combination of betaxolol (0.25%) and pilocarpine (1.75%), used 3 times daily in Studies 1 and 2; 2 times daily in Study 3.
Number of subjects: 534
Study 8981691 — intervention group
Group type: COMPARATOR
Intervention: Betaxolol (0.25%) alone, used 3 times daily in Studies 1 and 2; 2 times daily in Study 3.
Number of subjects: 534
Study 8981691 — intervention group
Group type: COMPARATOR
Intervention: Pilocarpine (1.75%) alone, used 3 times daily in Studies 1 and 2; 2 times daily in Study 3.
Number of subjects: 534
Study 8981691 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed combination of betaxolol and pilocarpine with surfactant, used 2 times daily in Study 3.
Number of subjects: 534
Study 1289101 — intervention group
Group type: EXPERIMENTAL
Intervention: Alteplase (tPA)
Number of subjects: 20891
Study 1289101 — intervention group
Group type: COMPARATOR
Intervention: Streptokinase (SK)
Number of subjects: 20891
Study 1289101 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin
Number of subjects: 20891
Study 1289101 — intervention group
Group type: COMPARATOR
Intervention: No Heparin
Number of subjects: 20891
Study 1289101 — intervention group
Group type: EXPERIMENTAL
Intervention: SK plus Heparin
Number of subjects: 20891
Study 3905057 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 780
Study 3905057 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 780
Study 3905057 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical therapy with exercise-induced angina
Number of subjects: 780
Study 3905057 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy with exercise-induced angina
Number of subjects: 780
Study 30946974 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief psychosocial intervention
Number of subjects: 406
Study 30946974 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy
Number of subjects: 406
Study 30946974 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term psychoanalytic psychotherapy
Number of subjects: 406
Study 30946974 — intervention group
Group type: COMPARATOR
Intervention: Dropouts (no specific intervention)
Number of subjects: 406
Study 29872997 — intervention group
Group type: EXPERIMENTAL
Intervention: Running on a treadmill
Number of subjects: 24
Study 29872997 — intervention group
Group type: COMPARATOR
Intervention: Watching a video
Number of subjects: 24
Study 26663710 — intervention group
Group type: EXPERIMENTAL
Intervention: 3DCRT/IMRT
Number of subjects: 254
Study 26663710 — intervention group
Group type: COMPARATOR
Intervention: 2DRT
Number of subjects: 254
Study 25174776 — intervention group
Group type: EXPERIMENTAL
Intervention: iopromide 370 mgI/mL
Number of subjects: 144
Study 25174776 — intervention group
Group type: COMPARATOR
Intervention: iopromide 300 mgI/mL
Number of subjects: 144
Study 22884306 — intervention group
Group type: EXPERIMENTAL
Intervention: Family focused treatment for adolescents (FFT‐A)
Number of subjects: 53
Study 22884306 — intervention group
Group type: COMPARATOR
Intervention: Enhanced care (a briefer psychoeducational treatment)
Number of subjects: 53
Study 20179283 — intervention group
Group type: EXPERIMENTAL
Intervention: ScvO2 group (resuscitated to normalize central venous pressure, mean arterial pressure, and ScvO2 of at least 70%)
Number of subjects: 300
Study 20179283 — intervention group
Group type: COMPARATOR
Intervention: Lactate clearance group (resuscitated to normalize central venous pressure, mean arterial pressure, and lactate clearance of at least 10%)
Number of subjects: 300
Study 17414228 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 50
Study 17414228 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 15623998 — intervention group
Group type: EXPERIMENTAL
Intervention: Amalgam (Megalloy)
Number of subjects: 40
Study 15623998 — intervention group
Group type: EXPERIMENTAL
Intervention: Bonding agent (Syntac) with amalgam
Number of subjects: 40
Study 15623998 — intervention group
Group type: EXPERIMENTAL
Intervention: Amalgam with adhesive resin luting agent (Resinomer)
Number of subjects: 40
Study 15623998 — intervention group
Group type: COMPARATOR
Intervention: Control (not restored)
Number of subjects: 40
Study 11850771 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 50
Study 11850771 — intervention group
Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 50
Study 11850771 — intervention group
Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 50
Study 10610086 — intervention group
Group type: EXPERIMENTAL
Intervention: Health and nutrition intervention in 24 schools over six years
Number of subjects: 40
Study 10610086 — intervention group
Group type: COMPARATOR
Intervention: Control group of 16 schools
Number of subjects: 40
Study 7626876 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm blood cardioplegia with continuous ante‐retrograde combined delivery during normothermic CPB
Number of subjects: 100
Study 7626876 — intervention group
Group type: COMPARATOR
Intervention: Cold blood intermittent cardioplegia plus topical ice slush in hypothermic CPB
Number of subjects: 100
Study 2275323 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (PPF)
Number of subjects: 30
Study 2275323 — intervention group
Group type: COMPARATOR
Intervention: Midazolam (MDZ)
Number of subjects: 30
Study 2275323 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (MDZ) with Flumazenil (FMZ)
Number of subjects: 30
Study 7356904 — intervention group
Group type: EXPERIMENTAL
Intervention: Codeine
Number of subjects: 0
Study 7356904 — intervention group
Group type: EXPERIMENTAL
Intervention: Promethazine plus codeine
Number of subjects: 0
Study 7356904 — intervention group
Group type: EXPERIMENTAL
Intervention: Codeine in smokers
Number of subjects: 0
Study 31443226 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest quartile of dietary acid load
Number of subjects: 3042
Study 31443226 — intervention group
Group type: COMPARATOR
Intervention: Lowest quartile of dietary acid load
Number of subjects: 3042
Study 28106665 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal denervation (RDN)
Number of subjects: 17
Study 28106665 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 17
Study 25471205 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 104
Study 25471205 — intervention group
Group type: EXPERIMENTAL
Intervention: Early PCI (within 2 weeks after last ischemic episode)
Number of subjects: 104
Study 25471205 — intervention group
Group type: EXPERIMENTAL
Intervention: Preprocedural variables
Number of subjects: 104
Study 25471205 — intervention group
Group type: EXPERIMENTAL
Intervention: Procedural variables
Number of subjects: 104
Study 25471205 — intervention group
Group type: EXPERIMENTAL
Intervention: Lesion characteristics
Number of subjects: 104
Study 25062336 — intervention group
Group type: EXPERIMENTAL
Intervention: prednisolone acetate 1%
Number of subjects: 325
Study 25062336 — intervention group
Group type: COMPARATOR
Intervention: fluorometholone 0.1%
Number of subjects: 325
Study 22500578 — intervention group
Group type: EXPERIMENTAL
Intervention: Maxillary advancement
Number of subjects: 48
Study 22500578 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular set back
Number of subjects: 48
Study 22500578 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimaxillary surgery
Number of subjects: 48
Study 20025372 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief mindfulness-based instructions
Number of subjects: 123
Study 20025372 — intervention group
Group type: COMPARATOR
Intervention: No-instruction control group
Number of subjects: 123
Study 17336181 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human epidermal growth factor 1‐48 (EGF(1‐48)) at 100 ng kg(‐1) h(‐1) for 6 days
Number of subjects: 8
Study 17336181 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 15181565 — intervention group
Group type: EXPERIMENTAL
Intervention: rIFN-gamma 1b (100 microg)
Number of subjects: 75
Study 15181565 — intervention group
Group type: EXPERIMENTAL
Intervention: rIFN-gamma 1b (200 microg)
Number of subjects: 75
Study 15181565 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75